Geneoscopy announced that the U.S. Patent Trial and Appeal Board (PTAB) invalidated all challenged claims of Exact Sciences’ ’746 patent — the second ruling in its favor after a prior decision invalidated claims in Exact’s ’781 patent.
With both patents now invalidated at the PTAB level, Geneoscopy has effectively removed the patent claims asserted against its RNA-based colorectal cancer screening test, ColoSense®, in ongoing litigation.
The ruling strengthens Geneoscopy’s position as it commercializes ColoSense, an FDA-approved stool-based RNA test for average-risk adults aged 45+.
Strategic implications:
- Clears a major intellectual property overhang
- Reduces litigation pressure tied to commercialization
- Intensifies competition in the noninvasive CRC screening market
- Signals growing differentiation between RNA-based and DNA-based stool platforms
The broader takeaway: the battle in stool-based colorectal cancer screening is shifting from patent defense to market execution.